Fennec's Pedmark meets in Phase III to prevent hearing loss associated with platinum-based chemotherapies

In October, Fennec Pharmaceuticals Inc. (TSX:FRX; NASDAQ:FENC) reported top-line data from the Phase III SIOPEL 6 trial in 99 children receiving platinum-based

Read the full 229 word article

User Sign In